As of Friday, December 26, Regencell Bioscience Holdings Limited’s RGC share price has dipped by 7.85%, which has investors questioning if this is right time to buy.
New PhD training programmes, delivered by Aberystwyth University with partner universities and industry, have been launched ...
Completes Repayment of Existing Credit Agreement, Extends Debt Maturity, and Enhances Financial FlexibilityBroadOak Partner ...
TipRanks on MSN
Zivo Bioscience CFO resigns, interim successor appointed
Zivo Bioscience ( ($ZIVO) ) has provided an update. On December 19, 2025, Zivo Bioscience’s Chief Financial Officer, Keith R. Marchiando, resigned ...
An update from Skye Bioscience ( ($SKYE) ) is now available. On December 18, 2025, Skye Bioscience, Inc. entered into a non-exclusive ...
Arizona’s students head back to school after winter break with sharpened pencils, fresh notebooks and renewed ambitions. But ...
SNB-101 previously received ODDs from the US FDA for small cell lung cancer in July 2023 and pancreatic cancer in February 2024. By receiving an ODD for gastric cancer this time, SN Bioscience expects ...
Vyne Therapeutics is set to combine with Yarrow Bioscience in an all-stock merger. Vyne, a clinical-stage biopharmaceutical company, and Yarrow Bioscience, a clinical-stage biotechnology company said ...
Harbour BioMed announced it has entered a multi-year, global strategic collaboration and license agreement with Bristol Myers ...
Yarrow Bioscience gets exclusive global rights for the GenSci098 therapy to treat thyroid eye disease and Graves’ disease.
York-based biotech firm Aptamer Group has announced a licensing agreement with synthetic biology and genomics company Twist ...
Maxis Venture Capital Portfolio Management is partnering with internationally recognized health care investment firm BioScience Managers to establish ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback